DaxibotulinumtoxinA
- Generic Name
- DaxibotulinumtoxinA
- Brand Names
- Botox, Botox Cosmetic, Daxxify, Dysport, Xeomin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 93384-43-1
- Unique Ingredient Identifier
- E211KPY694
- Background
DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. It is a botulinum toxin without accessory proteins purified from the bacterium Clostridium botulinum type A, the gram-positive anaerobic bacterium primarily present in soil. C. botulinum is known to produce toxins that can cause botulism in humans.
...
- Indication
DaxibotulinumtoxinA is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients. It is also used for the treatment of cervical dystonia in adult patients.
- Associated Conditions
- Cervical Dystonia, Moderate Glabellar Frown Lines (GL), Severe Glabellar Frown Lines (GL)
- Associated Therapies
- -
BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)
- Conditions
- Interventions
- Locations
- 🇺🇸
University of Texas Houston - Medical School, Houston, Texas, United States
Effect of Botulinum Toxin to Hallux Valgus in Addition to Total Contact Insole
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT01501500
- Locations
- 🇨🇳
Chang Gung MH, Gueishan, Taoyuan, Taiwan
Botulinum Toxin A for Treatment of Catocholamine Induced Finger Necrosis
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2012-01-05
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01500668
- Locations
- 🇮🇱
Sheba Medical Center, Tel-Hashomer, Israel
Brow Lifting With Dysport
- First Posted Date
- 2011-07-25
- Last Posted Date
- 2013-09-26
- Lead Sponsor
- Kenneth Beer
- Target Recruit Count
- 24
- Registration Number
- NCT01401803
- Locations
- 🇺🇸
Kenneth R. Beer, M.D., PA, West Palm Beach, Florida, United States
Upper Facial Remodeling With Perlane-L and Dysport
- Conditions
- Interventions
- First Posted Date
- 2011-05-17
- Last Posted Date
- 2013-09-26
- Lead Sponsor
- Beer, Kenneth R., M.D., PA
- Target Recruit Count
- 20
- Registration Number
- NCT01354743
- Locations
- 🇺🇸
Kenneth R. Beer, M.D., PA, West Palm Beach, Florida, United States
Safety and Efficacy Study of Botox in the Treatment of Forward Head Posture With Associated Episodic Headache Disorder
- Conditions
- Interventions
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- The Research Center of Southern California
- Target Recruit Count
- 30
- Registration Number
- NCT01350375
- Locations
- 🇺🇸
The Research Center of Southern California, Oceanside, California, United States
JCP Study of Investigation of Patient Background Characteristics
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2017-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 326
- Registration Number
- NCT01332474
Analgesic Effect of an Injection of Botulinum Toxin Type A in the Ganglion Impar in Patients With Chronic Proctalgia
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2013-10-07
- Lead Sponsor
- Nantes University Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT01331356
- Locations
- 🇫🇷
Centre Catherine de Sienne, Nantes, France
🇫🇷Nantes University Hospital, Nantes, France
Early Administration of Botox® in Neuropathic Pain Due to Thoracoscopy or Thoracotomy
- Conditions
- Interventions
- First Posted Date
- 2011-03-29
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- University Hospital, Limoges
- Registration Number
- NCT01325090
Brow Enhancement Study
- First Posted Date
- 2011-03-04
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- Skin Care and Laser Physicians of Beverly Hills
- Target Recruit Count
- 30
- Registration Number
- NCT01308593
- Locations
- 🇺🇸
Skin Care and Laser Physicians of Beverly Hills, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.